Ebpay
About Us
Corporate Profile
Management Team
Milestones
Awards
Our Vision
Affiliates
CTTQ Akesobio
Akeso Pharma
AD Pharmaceuticals
Contact Us
R&D and science
Technology Platform
Pipelines
Products Center
R&D and Manufacturing
Expanded Access Policy
Collaborations
Investor Relations
Financial Reports
Presentations
IR Monthly Reports
Announcements and Circulars
Corporate Governance
IR Calendar
IR Contact
Media
Career
Now Hiring
简
|
EN
|
2026-02-06
Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
2026-01-29
Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
2026-01-19
Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis
2026-01-14
Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer
2026-01-07
Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
2025-12-12
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
2025-12-09
Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
2025-12-07
All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs
2025-11-17
Akeso’s Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China
2025-11-10
Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer
2025-11-07
Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025
2025-11-07
Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74
1
2
3
4
5
6
7
8
9
»
